In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
After finishing at $438.93 in the prior trading day, Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) closed at $435.0%, Down $-0.90%. In other words, the price has decreased by -$0.90 from its previous closing price. On the day, 0.99 million shares were traded. ALNY stock price reached its highest trading level at $445.2 during the session, while it also had its lowest trading level at $426.19.
Ratios:
Our goal is to gain a better understanding of ALNY by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.75 and its Current Ratio is at 2.80. In the meantime, Its Debt-to-Equity ratio is 10.93 whereas as Long-Term Debt/Eq ratio is at 10.36.
On August 04, 2025, Oppenheimer Upgraded its rating to Outperform which previously was Perform but kept the price unchanged to $490.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on May 30 ’25 when Greenstreet Yvonne sold 31,640 shares for $304.39 per share. The transaction valued at 9,630,902 led to the insider holds 48,948 shares of the business.
Greenstreet Yvonne sold 19,297 shares of ALNY for $5,904,882 on Jun 02 ’25. The Chief Executive Officer now owns 48,948 shares after completing the transaction at $306.00 per share. On Jun 02 ’25, another insider, Greenstreet Yvonne, who serves as the Officer of the company, bought 19,297 shares for $303.10 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ALNY now has a Market Capitalization of 57019363328 and an Enterprise Value of 56901521408. For the stock, the TTM Price-to-Sale (P/S) ratio is 23.16 while its Price-to-Book (P/B) ratio in mrq is 227.36. Its current Enterprise Value per Revenue stands at 23.112 whereas that against EBITDA is -460.044.
Stock Price History:
The Beta on a monthly basis for ALNY is 0.31, which has changed by 0.6253784 over the last 52 weeks, in comparison to a change of 0.17279088 over the same period for the S&P500. Over the past 52 weeks, ALNY has reached a high of $439.36, while it has fallen to a 52-week low of $205.87. The 50-Day Moving Average of the stock is 30.36%, while the 200-Day Moving Average is calculated to be 57.14%.
Shares Statistics:
The stock has traded on average 1.01M shares per day over the past 3-months and 1554310 shares per day over the last 10 days, according to various share statistics. A total of 130.98M shares are outstanding, with a floating share count of 125.35M. Insiders hold about 4.37% of the company’s shares, while institutions hold 95.32% stake in the company. Shares short for ALNY as of 1752537600 were 3379378 with a Short Ratio of 3.34, compared to 1749772800 on 3375720. Therefore, it implies a Short% of Shares Outstanding of 3379378 and a Short% of Float of 3.4000000000000004.
Earnings Estimates
Investors are eagerly awaiting the insights provided by 14.0 analysts currently analyzing and rating the stock of Alnylam Pharmaceuticals Inc (ALNY).The consensus estimate for the next quarter is $2.25, with high estimates of $4.34 and low estimates of $0.68.
Analysts are recommending an EPS of between $6.54 and $2.88 for the fiscal current year, implying an average EPS of $3.92. EPS for the following year is $9.17, with 17.0 analysts recommending between $19.87 and $4.15.
Revenue Estimates
24 analysts predict $942.7M in revenue for the current quarter. It ranges from a high estimate of $1.27B to a low estimate of $805M. As of the current estimate, Alnylam Pharmaceuticals Inc’s year-ago sales were $500.92MFor the next quarter, 24 analysts are estimating revenue of $1.2B. There is a high estimate of $1.33B for the next quarter, whereas the lowest estimate is $928.13M.
A total of 28 analysts have provided revenue estimates for ALNY’s current fiscal year. The highest revenue estimate was $3.82B, while the lowest revenue estimate was $3.39B, resulting in an average revenue estimate of $3.5B. In the same quarter a year ago, actual revenue was $2.25BBased on 29 analysts’ estimates, the company’s revenue will be $4.83B in the next fiscal year. The high estimate is $7.61B and the low estimate is $2.81B.
